Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

Completed 82 enrolled University of Chicago Grifols Therapeutics LLC · collab Sunnybrook Health Sciences Centre · collab University of British Columbia · collab University of Tennessee · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Recurrent miscarriage is a prevalent reproductive problem that affects many couples who are trying to establish a family. This clinical study will evaluate the effectiveness of intravenous immunoglobulin (IVIG) in improving the live birth rate in couples who suffer from secondary recurrent miscarriage. This study will help in providing an answer to the question of whether IVIG is helpful in secondary recurrent miscarriage.

Timeline

Start: 1999-11
Primary completion: 2009-03
Completion: 2010-01

Publications

Stephenson MD, Kutteh WH, Purkiss S, Librach C, Schultz P, Houlihan E, Liao C. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial. Hum Reprod. 2010 Sep;25(9):2203-9. doi: 10.1093/humrep/deq179. Epub 2010 Jul 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Immune Globulin Intravenous (Human)	Protein / enzyme biologic	500 mg/kg	Intravenous

Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

Summary

Timeline

Publications

Drugs

Indications